US Bile Duct Cancer Market

ID: MRFR/Pharma/18334-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Bile Duct Cancer Market Research Report By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy), By Stage of Disease (Localized, Regional, Distant), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes) and By Diagnosis Type (Imaging Tests, Biopsy, Blood Tests) - Growth & Industry Forecast 2025 To 2035
US Bile Duct Cancer Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.81%
2024 Market Size$ 504.03 Million
2025 Market Size$ 528.28 Million
2035 Market Size$ 845.06 Million
Key Players
Roche
Novartis
Bristol-Myers Squibb
Merck & Co
AstraZeneca
Eli Lilly and Company
Trends
  • Emergence of Targeted Therapies
  • Increased Focus on Early Detection
  • Regulatory Changes and Accelerated Approvals
Opportunities
  • Increased Awareness and Education
  • Emergence of Personalized Medicine
  • Rising Incidence of Bile Duct Cancer
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Treatment Type (USD Million)
      1. 4.1.1 Surgery
      2. 4.1.2 Chemotherapy
      3. 4.1.3 Radiation Therapy
      4. 4.1.4 Targeted Therapy
      5. 4.1.5 Immunotherapy
    2. 4.2 Healthcare, BY Stage of Disease (USD Million)
      1. 4.2.1 Localized
      2. 4.2.2 Regional
      3. 4.2.3 Distant
    3. 4.3 Healthcare, BY End User (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Clinics
      3. 4.3.3 Ambulatory Surgical Centers
      4. 4.3.4 Cancer Research Institutes
    4. 4.4 Healthcare, BY Diagnosis Type (USD Million)
      1. 4.4.1 Imaging Tests
      2. 4.4.2 Biopsy
      3. 4.4.3 Blood Tests
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 AstraZeneca (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Amgen (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Gilead Sciences (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY STAGE OF DISEASE
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 US MARKET ANALYSIS BY DIAGNOSIS TYPE
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 HEALTHCARE, BY STAGE OF DISEASE, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY STAGE OF DISEASE, 2024 TO 2035 (USD Million)
    16. 6.16 HEALTHCARE, BY END USER, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
    18. 6.18 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY STAGE OF DISEASE, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
      4. 7.2.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Bile Duct Cancer Market Segmentation

US Bile Duct Cancer Market By Treatment Type (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy

US Bile Duct Cancer Market By Stage of Disease (USD Million, 2025-2035)

  • Localized
  • Regional
  • Distant

US Bile Duct Cancer Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

US Bile Duct Cancer Market By Diagnosis Type (USD Million, 2025-2035)

  • Imaging Tests
  • Biopsy
  • Blood Tests

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.